DFX Intelligence
Data Factory
Reading the graph
Reading the graph
Private Equity
London
Data as of (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built and rebuilt at most every 15 minutes.
| Fund | Vintage | Lifecycle | ADV type | Form D sold | GAV | LPs |
|---|---|---|---|---|---|---|
| 4bio Ventures III LP | 2023 | Early deployment | Private Equity Fund | n/a | $49.2M | 0 |
| 4bio Ventures II LP | n/a | Unknown | Private Equity Fund | n/a | $110M | 0 |
| Company | State | Role | Control | Invested | Exited | Status |
|---|---|---|---|---|---|---|
| UK Private Capital Member () LR | n/a | unknown | unknown | n/a | n/a | unknown |
Also named here, with no published line of their own (reach them through the firm): Abbas Hussain (Former CEO, Vifor Pharma; Global President Pharmaceuticals and Vaccines, GSK), Kieran Mudryy (Partner, General Counsel, Chief Compliance Officer), Andrey Kozlov (Managing Partner), Dmitry Andrew Kuzmin (Managing Partner).
Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan